ICON Public Limited (NASDAQ:ICLR) Holdings Lifted by GAMMA Investing LLC

GAMMA Investing LLC boosted its holdings in ICON Public Limited (NASDAQ:ICLR) by 64.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 433 shares of the medical research company’s stock after acquiring an additional 169 shares during the quarter. GAMMA Investing LLC’s holdings in ICON Public were worth $91,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Foyston Gordon & Payne Inc acquired a new position in shares of ICON Public in the 3rd quarter worth approximately $11,672,000. Icon Wealth Advisors LLC grew its position in ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after buying an additional 11,840 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in shares of ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after buying an additional 151 shares in the last quarter. Arkadios Wealth Advisors lifted its position in shares of ICON Public by 5.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock valued at $371,000 after acquiring an additional 62 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in shares of ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Trading Down 0.5 %

NASDAQ ICLR opened at $218.22 on Friday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public Limited has a 1-year low of $183.38 and a 1-year high of $347.72. The firm’s fifty day simple moving average is $211.33 and its 200-day simple moving average is $271.77. The company has a market capitalization of $18.00 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the company earned $3.10 earnings per share. As a group, sell-side analysts anticipate that ICON Public Limited will post 13.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ICLR has been the topic of a number of recent analyst reports. Evercore ISI cut their target price on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Citigroup cut their price objective on ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Leerink Partners reiterated an “outperform” rating and issued a $255.00 target price (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. The Goldman Sachs Group cut their price target on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Finally, Barclays decreased their price objective on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $287.00.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.